News / Finance
WhisperfromWallStreet.com "NASDAQ Afternoon Gainers" - Celldex Therapeutics, Inc,CLDX - Cardica, Inc.,CRDC - etrials Worldwide, Inc.,ETWC
Celldex Therapeutics, Inc - Cardica, Inc. - etrials Worldwide, Inc.
Celldex Therapeutics, Inc,CLDX
Celldex Therapeutics' proposed acquisition of CuraGen Corporation will expand Celldex's Precision Targeted Immunotherapy Platform with the addition of a robust portfolio of 11 oncology-focused antibodies. The proposed acquisition will also further strengthen Celldex's intellectual property estate, its balance sheet and support the potential development of additional value-creating milestones and partnering opportunities.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Cardica, Inc.,CRDC
Cardica, Inc. designs, manufactures, and markets proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass surgery. The company's products include C-Port Distal Anastomosis System, which is designed to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis System that includes modifications to the C-Port xA system designed to enable automated anastomoses to be performed as part of minimally invasive and robot-facilitated CABG procedures; and C-Port X-CHANGE system, a cartridge-based reloadable C-Port system.
---
etrials Worldwide, Inc.,ETWC
Medical imaging and information software company Merge Healthcare Inc. said Monday it is buying Etrials Worldwide Inc. for about $18.3 million in a cash-and-stock deal.
Milwaukee-based Merge said it will pay 80 cents and 0.3448 shares of Merge common stock for each of Etrials common shares, amounting to about $1.70 per share. That marks a 32 percent premium to Etrial's closing stock price of $1.29 Friday.
Newtown, Pa.-based Bio-Imaging's last offer included 0.124 shares of newly issued Bio-Imaging common stock, 0.076 shares of newly issued Bio-Imaging preferred stock, and 62 cents per share. That amounted to $1.35 per share.
---
Do not invest in these stocks because we mentioned them in this release. We never include our picks in these news releases. This is just to alert you to our service. Our alerts are saved for our subscribers. To receive Alerts on the stock we feel are going to move, sign up for our free alert service.
Visit WhisperfromWallStreet.com to sign up for your FREE subscription or download our free Windows Vista or iGoogle gadget for instant alerts direct to your desktop or iGoogle page.
If you are a public company looking to generate investor awareness for your company please contact us at info@WhisperfromWallStreet.com.
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com 585-301-7700
